AptaBio Therapeutics Inc (293780) — Financial Flexibility Index
AptaBio Therapeutics Inc (293780) has a Financial Flexibility Index of -0.12x as of September 2025. Free cash flow of ₩-2.71 Billion (operating CF ₩-2.73 Billion minus capex ₩16.17 Million) represents 0% of total liabilities (₩22.51 Billion). Check AptaBio Therapeutics Inc (293780) strategic investment index to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
AptaBio Therapeutics Inc Financial Flexibility Index (2017–2024)
Historical Financial Flexibility Index trend for AptaBio Therapeutics Inc across 8 annual periods. See working capital to net assets of AptaBio Therapeutics Inc to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for AptaBio Therapeutics Inc (2017–2024)
Year-by-year free cash flow to debt coverage for AptaBio Therapeutics Inc. For the full company profile including market capitalisation, see AptaBio Therapeutics Inc market cap and net worth.
| Year | Flexibility Index | Free Cash Flow (KRW) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -0.51x | ₩-11.92 Billion | ₩-12.16 Billion | ₩23.24 Billion | ▼ -14.7% |
| 2023 | -0.45x | ₩-13.93 Billion | ₩-14.10 Billion | ₩31.16 Billion | ▲ +71.1% |
| 2022 | -1.55x | ₩-5.79 Billion | ₩-6.83 Billion | ₩3.74 Billion | ▲ +42.5% |
| 2021 | -2.69x | ₩-8.74 Billion | ₩-8.90 Billion | ₩3.25 Billion | ▼ -337.5% |
| 2020 | -0.62x | ₩-2.09 Billion | ₩-3.79 Billion | ₩3.40 Billion | ▲ +57.0% |
| 2019 | -1.43x | ₩-3.22 Billion | ₩-6.00 Billion | ₩2.25 Billion | ▼ -67.7% |
| 2018 | -0.85x | ₩-1.72 Billion | ₩-1.75 Billion | ₩2.02 Billion | ▼ -1937.4% |
| 2017 | -0.04x | ₩-1.78 Billion | ₩-1.79 Billion | ₩42.54 Billion | — |